A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side effects.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Not only did people taking tirzepatide lose more weight overall, but more of them reached key weight-loss milestones. Nearly one-third of tirzepatide users lost at least 25% of their body weight.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

TIRZEPATIDE, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has emerged as a promising therapy for adults with Type 2 diabetes (T2D) or ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes, according ...